Effects of combined dietary supplementation with fenofibrate and Schisandrae Fructus pulp on lipid and glucose levels and liver function in normal and hypercholesterolemic mice

References

• LiWWangDSongGZuoCQiaoXQinSThe effect of combination therapy of allicin and fenofibrate on high fat diet-induced vascular endothelium dysfunction and liver damage in ratsLipids Health Dis2010913121073749
   PubMed Web of Science ®Google Scholar
• ParikhNHParikhPKKothariCIndigenous plant medicines for health care: treatment of diabetes mellitus and hyperlipidemiaChin J Nat Med201412533534424856756
   PubMed Web of Science ®Google Scholar
• BauerUEBrissPAGoodmanRABowmanBAPrevention of chronic disease in the 21st century: elimination of the leading preventable causes of premature death and disability in the USALancet20143849937455224996589
   PubMed Web of Science ®Google Scholar
• PanSYGaoSHZhouSFTangMKYuZLKoKMNew perspectives on complementary and alternative medicine: an overview and alternative therapyAltern Ther Health Med2012184203622875591
   PubMed Web of Science ®Google Scholar
• KeatingGMCroomKFFenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitusDrugs200767112115317209672
   PubMed Web of Science ®Google Scholar
• IkewakiKTohyamaJNakataYWakikawaTKidoTMochizukiSFenofibrate effectively reduces remnants, and small dense LDL, and increases HDL particle number in hypertriglyceridemic men – a nuclear magnetic resonance studyJ Atheroscler Thromb200411527828515557710
   PubMedGoogle Scholar
• OhtaTMasutomiNTsutsuiNUntargeted metabolomics profiling as an evaluative tool of fenofibrate-induced toxicology in Fischer 344 male ratsToxicol Pathol200937452153519458390
   PubMed Web of Science ®Google Scholar
• HajduDAiglováKVinklerováIUrbánekKAcute cholestatic hepatitis induced by fenofibrateJ Clin Pharm Ther200934559960219744016
   PubMed Web of Science ®Google Scholar
• DohmenKWenCYNagaokaSFenofibrate-induced liver injuryWorld J Gastroenterol200511487702770316437706
   PubMed Web of Science ®Google Scholar
• PanossianAWikmanGPharmacology of Schisandra chinensis Bail.: an overview of Russian research and uses in medicineJ Ethnopharmacol2008118218321218515024
   PubMed Web of Science ®Google Scholar
• XiongJGuoYLiLYA herbal composition of semen hoveniae, radix puerariae, and Fructus Schisandrae shows potent protective effects on acute alcoholic intoxication in rodent modelsEvid Based Complement Alternat Med2012201263819723118795
   PubMed Web of Science ®Google Scholar
• XieWDuLDiabetes is an inflammatory disease: evidence from traditional Chinese medicinesDiabetes Obes Metab201113428930121205111
   PubMed Web of Science ®Google Scholar
• JeongSIKimSJKwonTHYuKYKimSYSchizandrin prevents damage of murine mesangial cells via blocking NADPH oxidase-induced ROS signaling in high glucoseFood Chem Toxicol2012503–41045105322138248
   PubMed Web of Science ®Google Scholar
• KwonDYKim daSYangHJParkSThe lignan-rich fractions of Fructus Schisandrae improve insulin sensitivity via the PPAR-γ pathways in in vitro and in vivo studiesJ Ethnopharmacol2011135245546221440615
   PubMed Web of Science ®Google Scholar
• PanSYYuQZhangYDietary Fructus Schisandrae extracts and fenofibrate regulate the serum/hepatic lipid-profile in normal and hypercholesterolemic mice, with attention to hepatotoxicityLipids Health Dis20121112022989092
   PubMed Web of Science ®Google Scholar
• SunNPanSYZhangYDietary pulp from Fructus Schisandra chinensis supplementation reduces serum/hepatic lipid and hepatic glucose levels in mice fed a normal or high cholesterol/bile salt dietLipids Health Dis2014134624621253
   PubMed Web of Science ®Google Scholar
• WangXYYuZLPanSYSupplementation with the extracts of Schisandrae Fructus pulp, seed, or their combination influences the metabolism of lipids and glucose in mice fed with normal and hypercholesterolemic dietEvid Based Complement Alternat Med2014201447263824876871
   PubMed Web of Science ®Google Scholar
• PanSYDongHZhaoXYSchisandrin B from Schisandra chinensis reduces hepatic lipid contents in hypercholesterolaemic miceJ Pharm Pharmacol200860339940318284822
   PubMed Web of Science ®Google Scholar
• PanSYYangRDongHYuZLKoKMBifendate treatment attenuates hepatic steatosis in cholesterol/bile salt- and high-fat diet-induced hypercholesterolemia in miceEur J Pharmacol20065521–317017517046746
   PubMed Web of Science ®Google Scholar
• PanSYDongHYuZLBicyclol, a synthetic dibenzocyclooctadiene derivative, decreases hepatic lipids but increases serum triglyceride level in normal and hypercholesterolaemic miceJ Pharm Pharmacol200759121657166218053327
   PubMed Web of Science ®Google Scholar
• HuWLIYZhangCZEnantioseparation of racemic anti-hepatitis new drug bicyclol with crystallizationChin Chem Lett2005161114711473
   Web of Science ®Google Scholar
• LiXZhouJChenSRole of bicyclol in preventing chemotherapeutic agent-induced liver injury in patients over 60 years of age with cancerJ Int Med Res201442490699124903556
   PubMed Web of Science ®Google Scholar
• LiuGTBicyclol: a novel drug for treating chronic viral hepatitis B and CMed Chem200951294319149648
   PubMed Web of Science ®Google Scholar
• KumarDSPrashanthiGAvasaralaHBanjiDAntihypercholesterolemic effect of Macrotyloma uniflorum (Lam.) Verdc (Fabaceae) extract on high-fat diet-induced hypercholesterolemia in Sprague-Dawley ratsJ Diet Suppl201310211612823725525
   PubMedGoogle Scholar
• LinZJZhangBLiuXQYangHLAbdominal fat accumulation with hyperuricemia and hypercholesterolemia quail model induced by high fat dietChin Med Sci J200924319119419848323
   PubMedGoogle Scholar
• SharrettARBallantyneCMCoadySAAtherosclerosis Risk in Communities Study GroupCoronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein (a), apolipoproteins A-I and B, and HDL density subfraction: the atherosclerosis risk in communities (ARIC) studyCirculation2001104101108111311535564
   PubMed Web of Science ®Google Scholar
• BarterPGottoAMLaRosaJCTreating to New Targets InvestigatorsHDL cholesterol, very low levels of LDL cholesterol, and cardiovascular eventsN Engl J Med2007357131301131017898099
   PubMed Web of Science ®Google Scholar
• HsiaSHPanDBerookimPLeeMLA population-based, cross-sectional comparison of lipid-related indexes for symptoms of atherosclerotic diseaseAm J Cardiol20069881047105217027569
   PubMed Web of Science ®Google Scholar
• AndersonTJGrégoireJHegeleRA2012 update of the Canadian cardiovascular society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adultCan J Cardiol201329215116723351925
   PubMed Web of Science ®Google Scholar
• DengBOuSQZhengZFThe relationship of LDL-c/HDL-c ratio with coronary artery disease degree and acute coronary syndromesChin J Hypertension2005139541544
   Google Scholar
• BaligadooSElevated coronary mortality in Mauritius: risk factors and genetic analysesBull Acad Natl Med201219671381139423815022
   PubMed Web of Science ®Google Scholar
• SchofieldJDLiuYFranceMWSandleLSoranHA review of paradoxical HDL-C responses to fenofibrate, illustrated by a case reportJ Clin Lipidol20148445545925110229
   PubMed Web of Science ®Google Scholar
• LinzPELovatoLCByingtonRPParadoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid TrialDiabetes Care201437368669324296848
   PubMed Web of Science ®Google Scholar
• LellaMIndiraKA comparative study of efficacy of atorvastatin alone and its combination with fenofibrate on lipid profile in type 2 diabetes mellitus patients with hyperlipidemiaJ Adv Pharm Technol Res20134316617024083205
   PubMedGoogle Scholar
• NiesorEJGauthamadasaKSilvaRAXanthophylls, phytosterols and pre-β1-HDL are differentially affected by fenofibrate and niacinHDL-raising in a cross-over studyLipids201348121185119624068631
   PubMed Web of Science ®Google Scholar
• EnomotoMAdachiHHiraiYLDL-C/HDL-C ratio predicts carotid intima-media thickness progression better than HDL-C or LDL-C aloneJ Lipids2011201154913721773051
   PubMedGoogle Scholar
• TrapaniLSegattoMPallottiniVRegulation and deregulation of cholesterol homeostasis: the liver as a metabolic “power station”World J Hepatol20124618419022761969
   PubMedGoogle Scholar
• ChuJHWangHYeYInhibitory effect of schisandrin B on free fatty acid-induced steatosis in L-02 cellsWorld J Gastroenterol201117192379238821633637
   PubMed Web of Science ®Google Scholar
• EspenshadePJHughesALRegulation of sterol synthesis in eukaryotesAnnu Rev Genet20074140142717666007
   PubMed Web of Science ®Google Scholar
• XuXSoJSParkJGLeeAHTranscriptional control of hepatic lipid metabolism by SREBP and ChREBPSemin Liver Dis201333430131124222088
   PubMed Web of Science ®Google Scholar
• GrubenNShiri-SverdlovRKoonenDPHofkerMHNonalcoholic fatty liver disease: a main driver of insulin resistance or a dangerous liaison?Biochim Biophys Acta20141842112329234325128743
   PubMed Web of Science ®Google Scholar
• KellyCTMansoorJDohmGLChapmanWH3rdPenderJR4thPoriesWJHyperinsulinemic syndrome: the metabolic syndrome is broader than you thinkSurgery2014156240541124962189
   PubMed Web of Science ®Google Scholar
• SmithBWAdamsLANon-alcoholic fatty liver diseaseCrit Rev Clin Lab Sci20114839711321875310
   PubMed Web of Science ®Google Scholar
• JeongSYoonMFenofibrate inhibits adipocyte hypertrophy and insulin resistance by activating adipose PPAR alpha in high fat diet-induced obese miceExp Mol Med200941639740519322024
   PubMed Web of Science ®Google Scholar
• KostapanosMSKeiAElisafMSCurrent role of fenofibrate in the prevention and management of non-alcoholic fatty liver diseaseWorld J Hepatol20135947047824073298
   PubMedGoogle Scholar
• KwonDYda KimSYangHJParkSThe lignan-rich fractions of Fructus Schisandrae improve insulin sensitivity via the PPAR-γ pathways in in vitro and in vivo studiesJ Ethnopharmacol2011135245546221440615
   PubMed Web of Science ®Google Scholar
• JosephBKapoorSSchilskyMLGuptaSBile salt-induced pro-oxidant liver damage promotes transplanted cell proliferation for correcting Wilson disease in the long-evans cinnamon rat modelHepatology20094951616162419185006
   PubMed Web of Science ®Google Scholar
• CanetMJCherringtonNJDrug disposition alterations in liver disease: extrahepatic effects in cholestasis and nonalcoholic steatohepatitisExpert Opin Drug Metab Toxicol20141091209121924989624
   PubMed Web of Science ®Google Scholar
• KobayashiASuzukiYKunoHSugaiSSakakibaraHShimoiKEffects of fenofibrate on plasma and hepatic transaminase activities and hepatic transaminase gene expression in ratsJ Toxicol Sci200934437738719652460
   PubMed Web of Science ®Google Scholar
• GuoLYHungTMBaeKHAnti-inflammatory effects of schisandrin isolated from the fruit of Schisandra chinensis BaillEur J Pharmacol20085911–329329918625216
   PubMed Web of Science ®Google Scholar
• LouXEXuNYaoHPChenZBicyclol attenuates pro-inflammatory cytokine and chemokine productions in CpG-DNA-stimulated L02hepatocytes by inhibiting p65-NF-kappaB and p38-MAPK activationPharmazie201065320621220383942
   PubMed Web of Science ®Google Scholar
• ZhangYPanSYZhouSFTime- and dose-toxicity relationships of schisandrin B- and Schisandrae Fructus oil-induced hepatotoxicity associated with triglyceride elevation in serum and liver in miceDrug Des Devel Ther2014814291439
   Web of Science ®Google Scholar
• KonesRPrimary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive surveyDrug Des Devel Ther20115325380
   PubMed Web of Science ®Google Scholar